ArticleBMC infectious diseases2017
Antifungal susceptibility testing of Candida species isolated from the immunocompromised patients admitted to ten university hospitals in Iran: comparison of colonizing and infecting isolates.
Article in BMC infectious diseases, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it, 57 citations in OpenAlex.
- Pichia kudriavzevii (Candida krusei): A systematic review to inform the World Health Organisation priority list of fungal pathogens.Medical mycology · 2024Pooled it
- Phenotypic and Molecular Assessment ofPathogens (Basel, Switzerland) · 2026Article
- Antifungal and anti-virulence activities of cinnamon, thyme, and clove essential oils againstFrontiers in pharmacology · 2026Article
- Snakes as sentinel of zoonotic yeasts and bio-indicators of environmental quality.Scientific reports · 2024Article
- Hospitalized COVID-19 Patients with Urinary Tract Infection in Iran:Antibiotics (Basel, Switzerland) · 2024Article
- Identification and assessment of antifungal susceptibility ofIranian journal of microbiology · 2024Article
- Assessment of Risk Factors and Clinical Outcomes in Hospitalized COVID-19 Patients with Candida spp. Co-infections: Species Distribution and Antifungal Susceptibility Patterns of Isolates.Mycopathologia · 2023Article
- Antifungal Resistance of ClinicalIranian journal of public health · 2023Review
- Article
- In Silico and In Vitro Analysis of Sulforaphane Anti-Antibiotics (Basel, Switzerland) · 2022Article
- Distribution and antifungal susceptibility pattern ofVirulence · 2022Review
- A case of central nervous system infection byMedical mycology case reports · 2022Article
- Antifungal Susceptibility Testing Identifies the Abdominal Cavity as a Source of Candida glabrata-Resistant Isolates.Antimicrobial agents and chemotherapy · 2021Article
- The newly synthesized thiazole derivatives as potential antifungal compounds against Candida albicans.Applied microbiology and biotechnology · 2021Article
- Impact of antifungal stewardship interventions on the susceptibility of colonized Candida species in pediatric patients with malignancy.Scientific reports · 2021Article
- Comparison of the fungicidal efficacy of photodynamic therapy with methylene blue, silver nanoparticle, and their conjugation on oralCurrent medical mycology · 2020Article
- Isolation ofCurrent medical mycology · 2020Article
- In vitro antifungal susceptibilities of six antifungal drugs against clinicalCurrent medical mycology · 2020Article
- Amphotericin B Penetrates into the Central Nervous System Through Focal Disruption of the Blood Brain Barrier in Experimental HematogenousAntimicrobial agents and chemotherapy · 2019Article
- High prevalence of itraconazole resistance amongCurrent medical mycology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 11 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAntifungal susceptibility testing is a subject of interest in the field of medical mycology. The aim of the present study were the distributions and antifungal susceptibility patterns of various Candida species isolated from colonized and infected immunocompromised patients admitted to ten university hospitals in Iran.
methodsIn totally, 846 Candida species were isolated from more than 4000 clinical samples and identified by the API 20 C AUX system. Antifungal susceptibility testing was performed by broth microdilution method according to CLSI.
resultsThe most frequent Candida species isolated from all patients was Candida albicans (510/846). The epidemiological cutoff value and percentage of wild-type species for amphotericin B and fluconazole in Candida albicans, Candida tropicalis, Candida glabrata and Candida krusei were 0.5 μg/ml (95%) and 4 μg/ml (96%); 1 μg/ml (95%) and 8 μg/ml (95%); 0.5 μg/ml (99%) and 19 μg/ml (98%); and 4 μg/ml (95%) and 64 μg/ml (95%), respectively. The MIC90 and epidemiological cutoff values to posaconazole in Candida krusei were 0.5 μg/ml. There were significant differences between infecting and colonizing isolates of Candida tropicalis in MIC 90 values of amphotericin B, and isolates of Candida glabrata in values of amphotericin B, caspofungin, and voriconazole (P < 0.05).
conclusionsOur findings suggest that the susceptibility patterns of Candida species (colonizing and infecting isolates) in immunocompromised patients are not the same and acquired resistance was seen in some species.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.